Neuroimmunology includes applied and fundamental biology, immunology, neurology, chemistry, pathology, virology, and psychiatry of the central nervous system (CNS). The study of communications of the nervous system and immune is known as neuroimmunology. The development of the drug in neuroimmunology is anticipated to witness robust growth in the global market. The advancements in neurogenetics, fundamental pathology of the numerous diseases, and targeted therapy mechanism for drug development are some of the key factors boosting the neuroimmunology drugs market globally. The neuroimmunology drug market size is expected to reach US$ 37.32 Billion by 2030, growing at a CAGR of 6.93% over the forecast period of 2022-2030. The presence of a large number of drugs in clinical stages for the treatment of neuroimmunology diseases such as Multiple Sclerosis (MS), and Alzheimer’s disease (AD) is expected to generate immense opportunity for the market in the coming years. Additionally, numerous strategies opted by companies to develop advanced treatment options such as studying different targets for drug acting.
Small molecule and mAbs are the most common type of molecule in neuroimmunology, as they penetrate the blood-brain barrier. The high prevalence of neuroimmunology disease globally is expected to boost the demand for the drugs market in the coming years. According to the National MS Society, in 2019 about one million people living in the U.S. were suffering from multiple sclerosis. The number is twice of people suffering in 1975. The growing prevalence of neuroimmunology diseases is expected to generate substantial demand for advanced treatment options globally. However, the high cost associated with mAbs based therapy may hinder market growth significantly. However, research and development activities among research universities, hospitals, and companies operating in the market are projected to generate immense opportunities for the growth of the market globally.
The Global Neuroimmunology Drugs Market is segmented on the basis of indication, target type, and region. Based on the indication, the neuroimmunology drugs market is divided into Multiple Sclerosis (MS), Alzheimer’s disease (AD), and Others. The wide range of pipeline drugs for these indications are expected to boost the segmental growth during the estimated timeframe. The market is segmented into Cytokines, Lymphocytes or Molecules Associated with their Activation or Migration, and Others based on target type. The cytokines is the most common receptor for pipeline drugs of multiple sclerosis. About 35% of pipeline drugs for MS are targeting cytokine receptors. On the basis of the region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. The Asia Pacific is estimated to register high growth in the neuroimmunology drugs market during the estimated timeframe.
The key players of this market include F. Hoffmann-La Roche Ltd, Biogen, AstraZeneca Plc, T3D Therapeutics, Johnson & Johnson, Merck KGaA, Celgene Corp., Novartis AG, Sanofi, UCB SA, Eisai Co Ltd, Eli Lilly, Tiaki Therapeutics, AB Science S.A., ImmunoBrain Checkpoint, Actelion Pharmaceuticals Ltd., AstronauTx, Alector, AZTherapies Inc., INmune Bio, Inc., Lundbeck, Genetech Inc., Grifols SA, T.G. Therapeutics Inc., Talisman Therapeutics, AevisBio Inc., Monument Tx, Inflammasome Therapeutics, and TauRX Therapeutics Ltd among others.
